Co-Diagnostics Inc
NASDAQ:CODX
Net Margin
Co-Diagnostics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Co-Diagnostics Inc
NASDAQ:CODX
|
9.7m USD |
-1 025%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
218.9B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.7B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
159.4B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
153.2B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
118B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.3B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.3B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43.7B USD |
23%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
40.1B USD |
26%
|
Co-Diagnostics Inc
Glance View
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Co-Diagnostics Inc's most recent financial statements, the company has Net Margin of -1 025.3%.
You don't have any saved screeners yet